EcoDrugPlus

Integrin Beta-1-Like

Ensembl ID : ENSAOCG00000016345
Gene Symbol: LOC111563530
3 Cross references
209 Possible Orthologues:

Integrin Beta-1-Like

Ensembl ID : ENSAOCG00000002603
Gene Symbol: LOC111567785
3 Cross references
230 Possible Orthologues:

Integrin Beta-3-Like

Ensembl ID : ENSAOCG00000012710
Gene Symbol: LOC111584896
3 Cross references
204 Possible Orthologues:

Integrin Beta-5-Like

Ensembl ID : ENSAOCG00000023413
Gene Symbol: LOC111575940
3 Cross references
209 Possible Orthologues:

Integrin Beta-5-Like

Ensembl ID : ENSAOCG00000018098
Gene Symbol: LOC111578188
3 Cross references
209 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSAOCG00000009683
Gene Symbol: ITGA4
2 Cross references
226 Possible Orthologues:

Integrin Subunit Alpha 5

Ensembl ID : ENSAOCG00000011160
Gene Symbol: ITGA5
3 Cross references
196 Possible Orthologues:

Integrin Subunit Alpha V

Ensembl ID : ENSAOCG00000016939
Gene Symbol: ITGAV
3 Cross references
233 Possible Orthologues:

Integrin Subunit Beta 3

Ensembl ID : ENSAOCG00000003391
Gene Symbol: ITGB3
3 Cross references
195 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSAOCG00000010002
Gene Symbol: ITGB6
3 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSAOCG00000024235
Gene Symbol: ITGB8
3 Cross references
207 Possible Orthologues:

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSAOCG00000016335
Gene Symbol: IRAK4
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).